Is it justifiable to move the grade-1 Ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those

2024-11-1020200893-3952N/Ahttps://www.nature.com/articles/s41379-020-0482-7.pdfhttps://hdl.handle.net/20.500.14288/15760N/APathologyIs it justifiable to move the grade-1 Ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%Meeting Abstract1530-0285Q110669